BICX · BioCorRx Inc.

0001477932-26-001807

SEC filing

Summary

Revenue was $797.2K (10301.1%) Operating Income was -$4.8M (5.7%) Net Income was -$3.4M (34.0%) Eps was $-0.19

Key takeaways

Operating income loss improved 5.7% to -$4.8M versus -$5.1M prior year.
Net loss decreased 34.0% to -$3.4M from -$5.2M, driven by revenue growth, grant income, and reduced interest expenses despite higher operating costs.
Operating cash use intensified to -$2.3M from -$1.1M due to non-cash adjustments, operating asset growth, and operating liability decreases.

Full analysis

Looking ahead, the Company anticipates continued operating losses into 2026 as it pursues development plans and potential strategic initiatives, reliant on external financing. This trajectory emphasizes execution risks around clinical milestones, distribution expansion, and cost discipline to approach sustainability, with grant funding providing some near-term support but not altering the capital raise dependency.